World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
36825
World Ranking
10396
National Ranking
5352

Leo I. Gordon publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Leo I. Gordon sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 651 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Leo I. Gordon D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Leo I. Gordon sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Leo I. Gordon is affiliated with Northwestern University in the United States and has produced extensive research primarily within the field of medicine. Their work focuses on oncology, pathology and forensic medicine, genetics, immunology, and molecular biology. Their research contributions span more than 300 publications, with a significant emphasis on lymphoma diagnosis and treatment, CAR-T cell therapy research, and chronic lymphocytic leukemia research.

The main topics addressed in their research include:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Immunotherapy and Immune Responses
  • CNS Lymphoma Diagnosis and Treatment
  • Biosimilars and Bioanalytical Methods
  • Lung Cancer Treatments and Mutations

Leo I. Gordon frequently publishes alongside the following co-authors:

  • Reem Karmali
  • Jane N. Winter
  • Shuo Ma
  • Adam Yuh Lin
  • Jonathan Moreira

Their preferred publication venues include:

  • Blood
  • Journal of Clinical Oncology
  • Blood Advances
  • Transplantation and Cellular Therapy
  • Journal of the National Comprehensive Cancer Network

Selected recent papers authored by Leo I. Gordon include:

  • Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study, 2020, The Lancet
  • Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma, 2021, New England Journal of Medicine
  • Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study, 2022, The Lancet Oncology
  • NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021, 2021, Journal of the National Comprehensive Cancer Network
  • Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network

The scope and frequency of their publications demonstrate a sustained contribution to the advancement of therapeutic approaches and clinical guidelines in hematologic malignancies. The research includes clinical trials, guideline updates, and translational studies related to CAR-T cell therapies and lymphoma.

Best Publications

  • Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Leo I. Gordon;Fernando Cabanillas;Myron S. Czuczman

  • Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

    Jeremy S Abramson;M Lia Palomba;Leo I Gordon;Matthew A Lunning

  • Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

    Myron S. Czuczman;A. J. Grillo-López;C. A. White;M. Saleh

  • Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

    Kenneth R. Carson;Andrew M. Evens;Elizabeth A. Richey;Thomas M. Habermann

  • Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

    Anupama Reddy;Jenny Zhang;Nicholas S. Davis;Andrea B. Moffitt

  • Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis

    Sigmund A. Weitzman;Leo I. Gordon

  • An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

    Zheng Zhou;Laurie H. Sehn;Alfred W. Rademaker;Leo I. Gordon

  • Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Ian W. Flinn;Leo I. Gordon;Christos Emmanouilides

  • Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma

    Thomas E. Witzig;Christine A. White;Gregory A. Wiseman;Leo I. Gordon

  • Genetic heterogeneity of diffuse large B-cell lymphoma

    Jenny Zhang;Vladimir Grubor;Cassandra L. Love;Anjishnu Banerjee

  • The genetic landscape of mutations in Burkitt lymphoma

    Cassandra Love;Zhen Sun;Dereje Jima;Guojie Li

  • Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

    Philippe Armand;Arnon Nagler;Edie A. Weller;Steven M. Devine

  • Non-Hodgkin's Lymphomas

    Andrew D. Zelenetz;Ranjana H. Advani;John C. Byrd;Myron S. Czuczman

  • Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

    Bruce D. Cheson;Stephen Ansell;Larry Schwartz;Leo I. Gordon

  • Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's Lymphoma

    Leo I. Gordon;David Harrington;Janet Andersen;Joseph Colgan

  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

    Zelenetz Ad;Abramson Js;Advani Rh;Andreadis Cb

  • Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study

    Howard Hochster;Edie Weller;Randy D. Gascoyne;Thomas M. Habermann

  • Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

    Gregory A. Wiseman;Leo I Gordon;Pratik S. Multani;Thomas E. Witzig

  • EFFICACY AND SAFETY OF

    Mary Beth Riley;Leo I. Gordon

  • NCCN guidelines ® insights hodgkin lymphoma, version 1.2018 featured updates to the NCCN guidelines

    Richard T. Hoppe;Ranjana H. Advani;Weiyun Z. Ai;Richard F. Ambinder

Frequent Co-Authors

Ranjana H. Advani
Ranjana H. Advani Stanford University
Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Myron S. Czuczman
Myron S. Czuczman Citius Pharmaceuticals, Inc.
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Randy D. Gascoyne
Randy D. Gascoyne BC Cancer Agency
Alfred W. Rademaker
Alfred W. Rademaker Northwestern University
Richard T. Hoppe
Richard T. Hoppe Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine goes beyond traditional medical degrees. Numerous online degrees in nursing and healthcare offer flexible, affordable pathways for students and professionals seeking to advance or pivot their careers.

Many choose to begin their journey with adn nursing programs, which provide a foundational entry into nursing and can be a stepping stone to more advanced roles. For those already working as registered nurses, enrolling in one of the most affordable accredited online rn to bsn programs allows them to gain further qualifications and unlock new career opportunities.

Individuals from non-nursing backgrounds who wish to enter the nursing field can benefit from online msn programs for non nurses, which offer an accelerated path to advanced practice roles. For those aiming for the highest academic and professional levels, the cheapest phd nursing programs make earning a doctoral degree more accessible without compromising on quality.

These diverse online programs can help you tailor your educational path to your career goals in medicine and healthcare.

Best Scientists Citing Leo I. Gordon

Trending Scientists

Recently Published Articles